Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenabasum in dermatomyositis
NCT02466243Phase 2Terminated
- Sponsor
- Corbus Pharmaceuticals Holdings, Inc.
- Start
- Jun 2015
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenabasum in dermatomyositis (DM), sponsored by Corbus Pharmaceuticals Holdings, Inc.. Started Jun 2015; status: terminated.
02
Drugs
lenabasum
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT02466243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02466243.